Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting

BRISBANE, Calif., Oct. 17, 2022 -- Vera Therapeutics, Inc. , a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious... | October 17, 2022

Related Keywords

Florida ,United States ,Orange County Convention Center ,Brisbane ,Queensland ,Australia ,Orlando ,American ,Los Angeles ,Joyce Allaire ,Jonathan Barratt ,University Of Leicester ,Amplyx Pharmaceuticals Inc ,Sinai Medical Center ,Vera Therapeutics Inc ,Nasdaq ,Exchange Commission ,Pfizer Inc ,American Society Of Nephrology Kidney Week ,American Society ,Nephrology Kidney Week ,Randomized Phase ,Kidney Transplant ,Clinical Outcomes ,Transplant Immunology ,Cedars Sinai Medical Center ,David Geffen School ,Reduces Serum Immune Complex Levels ,Mayer Professor ,Renal Medicine ,Amplyx Pharmaceuticals ,Private Securities Litigation Reform Act ,Vera Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,022 ,Vera ,Biotechnology ,Company ,Ocused ,N ,Developing ,End ,Commercializing ,Ransformative ,Treatments ,Or ,Patients ,Ith Vera Us92337r1014 ,